RT Journal Article SR Electronic T1 Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5937 OP 5941 DO 10.21873/anticanres.12939 VO 38 IS 10 A1 OZAWA, YUICHI A1 KODA, KEIGO A1 AKAHORI, DAISUKE A1 MATSUI, TAKASHI A1 HASEGAWA, HIROTSUGU A1 KAKUTANI, TAKUYA A1 AMANO, TUSUKE A1 TANAHASHI, MASAYUKI A1 NIWA, HIROSHI A1 KUNIMOTO, YUKIHIRO A1 YAMADA, KAZUNARI A1 YOKOMURA, KOSHI A1 SUDA, TAKAFUMI YR 2018 UL http://ar.iiarjournals.org/content/38/10/5937.abstract AB Background/Aim: The aim of this study was to reveal risk factors for lung injury following irinotecan administration for the treatment of neoplasms. Patients and Methods: This study included 204 patients who received irinotecan from October 2005 to November 2014 and had evaluable chest CT images before initiation of irinotecan. Results: Six (2.9%) patients developed lung injury and, of these, 2 had preexisting interstitial lung disease (pre-ILD). The frequency of lung injury in patients with pre-ILD was 11% (2 of 19) while that in patients without pre-ILD was 2.2%. Risk factor analysis for the lung injury showed pre-ILD was the most predictable factor [odds ratio (OR) 5.00, p=0.07]. Combination with other agents, origin of neoplasms (lung or not), initial dose or minimum interval were not observed to be related to risk. Conclusion: The risk of lung injury with irinotecan was high when pre-ILD was present and the risk was comparable with previously reported other agents.